KRAS and breast cancer: For example, KRAS and PI3K have been found to cooperate in the production of de novo lipid biogenesis and RAS oncogenesis is exaggerated when the cyclin-dependent kinase inhibitor (p21WAF1/CIP1) is depleted in breast cancer [18,19,20].